Somewhat Positive Press Coverage Somewhat Unlikely to Impact NeuroMetrix (NURO) Stock Price
Media stories about NeuroMetrix (NASDAQ:NURO) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. NeuroMetrix earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned news stories about the medical device company an impact score of 46.2407270522759 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Shares of NeuroMetrix (NASDAQ:NURO) opened at $1.66 on Wednesday. NeuroMetrix has a fifty-two week low of $1.58 and a fifty-two week high of $11.04.
A number of equities research analysts recently weighed in on NURO shares. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target (down from $10.00) on shares of NeuroMetrix in a report on Friday, October 20th. Zacks Investment Research lowered shares of NeuroMetrix from a “buy” rating to a “hold” rating in a report on Tuesday, July 18th.
COPYRIGHT VIOLATION NOTICE: This story was published by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.watchlistnews.com/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-neurometrix-nuro-stock-price/1703720.html.
NeuroMetrix, Inc is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests.
Receive News & Ratings for NeuroMetrix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroMetrix Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.